PE20080858A1 - Compuestos de n-aril pirazol y composiciones que los contienen - Google Patents
Compuestos de n-aril pirazol y composiciones que los contienenInfo
- Publication number
- PE20080858A1 PE20080858A1 PE2007001365A PE2007001365A PE20080858A1 PE 20080858 A1 PE20080858 A1 PE 20080858A1 PE 2007001365 A PE2007001365 A PE 2007001365A PE 2007001365 A PE2007001365 A PE 2007001365A PE 20080858 A1 PE20080858 A1 PE 20080858A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- cycloalkyl
- compounds
- thiofen
- pyrimidin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 210000002660 insulin-secreting cell Anatomy 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85108306P | 2006-10-10 | 2006-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080858A1 true PE20080858A1 (es) | 2008-08-06 |
Family
ID=39047570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001365A PE20080858A1 (es) | 2006-10-10 | 2007-10-10 | Compuestos de n-aril pirazol y composiciones que los contienen |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8022061B2 (enExample) |
| EP (1) | EP2079728B1 (enExample) |
| JP (1) | JP2010505957A (enExample) |
| AR (1) | AR063240A1 (enExample) |
| AU (1) | AU2007308154A1 (enExample) |
| CA (1) | CA2675511A1 (enExample) |
| CL (1) | CL2007002904A1 (enExample) |
| ES (1) | ES2430821T3 (enExample) |
| MX (1) | MX2009003821A (enExample) |
| PE (1) | PE20080858A1 (enExample) |
| TW (1) | TW200831491A (enExample) |
| WO (1) | WO2008045484A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008068171A1 (en) | 2006-12-08 | 2008-06-12 | F. Hoffmann-La Roche Ag | Substituted pyrimidines and their use as jnk modulators |
| ES2551095T3 (es) * | 2007-07-19 | 2015-11-16 | Lundbeck, H., A/S | Amidas heterocíclicas de 5 miembros y compuestos relacionados |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| BRPI0816382A2 (pt) | 2007-09-06 | 2015-02-24 | Merck Sharp & Dohme | Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças |
| AU2010218224B2 (en) | 2009-02-26 | 2013-06-27 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2571359A4 (en) * | 2010-05-20 | 2013-10-23 | Merck Sharp & Dohme | NOVEL PROLYLCARBOXYPEPTIDASE HEMMER |
| EA023254B1 (ru) | 2010-05-27 | 2016-05-31 | Мерк Шарп Энд Домэ Корп. | Активаторы растворимой гуанилатциклазы |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| JP5605104B2 (ja) * | 2010-09-10 | 2014-10-15 | セントラル硝子株式会社 | ピラゾール化合物の製造方法 |
| AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| ES2707323T3 (es) | 2012-12-07 | 2019-04-03 | Chemocentryx Inc | Diazol lactamas |
| ES2648994T3 (es) * | 2012-12-21 | 2018-01-09 | Chemocentryx, Inc. | Diazolamidas como antagonistas del receptor CCR1 |
| CN103772282B (zh) * | 2014-02-26 | 2015-09-23 | 上海毕得医药科技有限公司 | 一种3-叔丁基-1h-吡唑-4-甲醛的制备方法 |
| WO2016138631A1 (en) | 2015-03-03 | 2016-09-09 | Eli Lilly And Company | Imidazo benzamide compounds |
| CN118994191A (zh) * | 2016-02-05 | 2024-11-22 | 戴纳立制药公司 | 受体相互作用蛋白激酶1的抑制剂 |
| WO2017176965A1 (en) | 2016-04-07 | 2017-10-12 | Chemocentryx, Inc. | Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors |
| HRP20220636T1 (hr) | 2016-12-09 | 2022-07-22 | Denali Therapeutics Inc. | Spojevi korisni kao inhibitori ripk1 |
| SG11202009179TA (en) * | 2018-04-04 | 2020-10-29 | Japan Tobacco Inc | Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof |
| WO2020007729A1 (en) | 2018-07-04 | 2020-01-09 | Boehringer Ingelheim International Gmbh | Triazole benzamide derivatives as gpr142 agonists |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| AU2023206890A1 (en) | 2022-01-12 | 2024-08-22 | Denali Therapeutics Inc. | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3778433A (en) * | 1969-04-18 | 1973-12-11 | Sumitomo Chemical Co | Process for producing benzodiazepine derivatives |
| US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| JPH04145081A (ja) | 1990-10-06 | 1992-05-19 | Kumiai Chem Ind Co Ltd | ピラゾールカルボン酸誘導体及び除草剤 |
| TW312694B (enExample) | 1994-09-26 | 1997-08-11 | Daiichi Seiyaku Co | |
| US5883105A (en) * | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AR038955A1 (es) | 1996-12-05 | 2005-02-02 | Amgen Inc | Compuestos de pirimidinona y piridona sustituidos y metodos para su uso |
| US6169086B1 (en) * | 1997-01-27 | 2001-01-02 | Daiichi Pharmaceutical Co., Ltd. | Pyrazole derivatives |
| CA2280515A1 (en) | 1997-03-11 | 1998-09-17 | E.I. Du Pont De Nemours And Company | Heteroaryl azole herbicides |
| JP4960565B2 (ja) | 2000-05-12 | 2012-06-27 | ジェンザイム コーポレーション | ＴＮＦαシグナル伝達のモジュレータ |
| WO2002023986A1 (en) | 2000-08-25 | 2002-03-28 | Sankyo Company, Limited | 4-acylaminopyrazole derivatives |
| US20040198758A1 (en) * | 2001-08-17 | 2004-10-07 | Rapado Liliana Parra | N-heterocyclyl substituted thienyloxy-pyrimidines used as herbicides |
| EP1451160B1 (en) * | 2001-11-01 | 2010-01-13 | Icagen, Inc. | Pyrazole-amides for use in the treatment of pain |
| DE10234876A1 (de) * | 2002-07-25 | 2004-02-05 | Bayer Cropscience Gmbh | 4-Trifluormethylpyrazolyl substituierte Pyridine und Pyrimidine |
| JP3774184B2 (ja) | 2002-10-25 | 2006-05-10 | 株式会社フジクラ | 光ファイバ心線テープ被覆除去具及び光ファイバ心線テープ被覆除去方法 |
| WO2004098518A2 (en) | 2003-05-01 | 2004-11-18 | Bristol-Myers Squibb Company | Pyrazole-amide compounds useful as kinase inhibitors |
| JP2004339080A (ja) | 2003-05-13 | 2004-12-02 | Tokyo Institute Of Technology | ピラゾ−ル誘導体を含有する高血圧治療剤 |
| US6818631B1 (en) * | 2003-08-15 | 2004-11-16 | Nippon Soda Co. Ltd. | Fungicidal pyrimidine derivatives |
| WO2005058883A1 (en) | 2003-12-15 | 2005-06-30 | Almirall Prodesfarma Ag | 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
| CA2564325A1 (en) | 2004-04-30 | 2005-11-24 | Bayer Pharmaceuticals Corporation | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| WO2008045664A2 (en) * | 2006-10-06 | 2008-04-17 | Kalypsys, Inc. | Heterocyclic pde4 inhibitors as antiinflammatory agents |
-
2007
- 2007-10-09 EP EP07839443.4A patent/EP2079728B1/en active Active
- 2007-10-09 WO PCT/US2007/021678 patent/WO2008045484A1/en not_active Ceased
- 2007-10-09 CA CA002675511A patent/CA2675511A1/en not_active Abandoned
- 2007-10-09 ES ES07839443T patent/ES2430821T3/es active Active
- 2007-10-09 JP JP2009532398A patent/JP2010505957A/ja not_active Withdrawn
- 2007-10-09 US US11/973,900 patent/US8022061B2/en not_active Expired - Fee Related
- 2007-10-09 CL CL200702904A patent/CL2007002904A1/es unknown
- 2007-10-09 MX MX2009003821A patent/MX2009003821A/es unknown
- 2007-10-09 AU AU2007308154A patent/AU2007308154A1/en not_active Abandoned
- 2007-10-09 TW TW096137866A patent/TW200831491A/zh unknown
- 2007-10-10 AR ARP070104489A patent/AR063240A1/es unknown
- 2007-10-10 PE PE2007001365A patent/PE20080858A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2675511A1 (en) | 2008-04-17 |
| ES2430821T3 (es) | 2013-11-21 |
| MX2009003821A (es) | 2009-05-25 |
| AR063240A1 (es) | 2009-01-14 |
| CL2007002904A1 (es) | 2008-06-06 |
| EP2079728B1 (en) | 2013-09-25 |
| TW200831491A (en) | 2008-08-01 |
| US8022061B2 (en) | 2011-09-20 |
| US20080153778A1 (en) | 2008-06-26 |
| AU2007308154A1 (en) | 2008-04-17 |
| JP2010505957A (ja) | 2010-02-25 |
| WO2008045484A1 (en) | 2008-04-17 |
| EP2079728A1 (en) | 2009-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080858A1 (es) | Compuestos de n-aril pirazol y composiciones que los contienen | |
| PE20090297A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis | |
| PE20070585A1 (es) | Derivados de sulfonamida como activadores de glucoquinasa | |
| PE20051173A1 (es) | Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3 | |
| PE20081532A1 (es) | Compuestos novedosos | |
| PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| PE20080069A1 (es) | Compuestos biciclicos como agonistas del receptor 40 acoplado a proteina g (gpr40) | |
| PE20141375A1 (es) | Activadores de glucoquinasa | |
| PE20060427A1 (es) | Derivados de pirazol como inhibidores de la union del glucagon y composiciones | |
| PE20081467A1 (es) | Compuestos de benzoil amino heterociclico como mediadores de glucoquinasas (glk) | |
| PE20091925A1 (es) | Derivados de indazol sustituidos con fenilo o benzodioxinilo | |
| PE20130242A1 (es) | Derivados de isoxazolo-piridina | |
| PE20140471A1 (es) | Moduladores de la via del complemento y usos de los mismos | |
| PE20110598A1 (es) | Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38 | |
| PE20050018A1 (es) | Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b) | |
| PE20081238A1 (es) | Piperidinas sustituidas como antagonistas de hdm2 | |
| PE20040702A1 (es) | Heterociclos diarilicos sustituidos y procedimiento para su preparacion como medicamentos | |
| PE20090237A1 (es) | Derivados de sulfonamidas como inhibidores de los canales de sodio | |
| PE20081659A1 (es) | Agonistas de gpcr | |
| PE20090884A1 (es) | Compuestos de indol como activadores de glucoquinasa | |
| PE20090150A1 (es) | Compuestos derivados de oxadiazol | |
| PE20080927A1 (es) | Derivados de benzoil-amino-heterociclilo como activadores de la glucoquinasa (glk) | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| CR8505A (es) | Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
| PE20070545A1 (es) | Derivados de fenil-[1,2,4]-oxadiazol-5-ona con grupo fenilo como agentes moduladores de ppar, composiciones farmaceuticas que los contienen y procedimientos para su preparacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |